핵산 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

Nucleic Acid Therapeutics Market - Scope of Report

TMR's report on the global nucleic acid therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global nucleic acid therapeutics market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nucleic acid therapeutics market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the nucleic acid therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global nucleic acid therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global nucleic acid therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global nucleic acid therapeutics market.

The report delves into the competitive landscape of the global nucleic acid therapeutics market. Key players operating in the global nucleic acid therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global nucleic acid therapeutics market profiled in this report.

Key Questions Answered in Global nucleic acid therapeutics market Report:

• What is the sales/revenue generated by nucleic acid therapeutics across all regions during the forecast period?
• What are the opportunities in the global nucleic acid therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Nucleic Acid Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global nucleic acid therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global nucleic acid therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global nucleic acid therapeutics market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nucleic Acid Therapeutics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Nucleic Acid Therapeutics Market Analysis and Forecast, 2020 - 2035
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Healthcare Expenditure across Key Regions / Countries
• 5.2. Technological Advancements in Nucleic Acid Therapeutics Industry
• 5.3. List of Nucleic Acid Therapeutics Approved by FDA
• 5.4. Nucleic Acid Therapeutics Pricing Trends
• 5.5. Nucleic Acid Therapeutics: Clinical Trial Analysis
• 5.6. Funding and Investments Analysis
• 5.7. PORTER's Five Forces Analysis
• 5.8. Regulatory Landscape across Key Regions / Countries
• 5.9. Go-to-Market Strategy for New Market Entrants
• 5.10. Key Purchase Metrics for End-users
• 5.11. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
• 5.12. Benchmarking of the Products Offered by the Leading Competitors
• 5.13. Preclinical Pipeline Analysis for Nucleic Acid Therapeutics

6. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Therapy Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Therapy Type, 2020 - 2035
  • 6.3.1. Antisense oligonucleotides (ASOs)
  • 6.3.2. Small interfering R(siRNA)
  • 6.3.3. Gene Therapies
  • 6.3.4. Aptamers
  • 6.3.5. Others
• 6.4. Market Attractiveness Analysis, by Therapy Type

7. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Delivery Method

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Delivery Method, 2020 - 2035
  • 7.3.1. Viral vector-based Delivery Systems
  • 7.3.2. Non-viral Delivery Systems
• 7.4. Market Attractiveness Analysis, by Delivery Method

8. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Route of Administration

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Route of Administration, 2020 - 2035
  • 8.3.1. Intravenous
  • 8.3.2. Subcutaneous
  • 8.3.3. Others
• 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Therapeutic Area

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Therapeutic Area, 2020 - 2035
  • 9.3.1. Neuromuscular Disorder
  • 9.3.2. Metabolic Disorders
  • 9.3.3. Cardiovascular Disorders
  • 9.3.4. Ophthalmological Disorders
  • 9.3.5. Oncological Disorders
  • 9.3.6. Others
• 9.4. Market Attractiveness Analysis, by Therapeutic Area

10. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by End-user

• 10.1. Introduction & Definition
• 10.2. Key Findings/Developments
• 10.3. Market Value Forecast, by End-user, 2020 - 2035
  • 10.3.1. Hospitals
  • 10.3.2. Academic and Research Institutes
  • 10.3.3. Others
• 10.4. Market Attractiveness Analysis, by End-user

11. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Region

• 11.1. Key Findings
• 11.2. Market Value Forecast, by Region, 2020 - 2035
  • 11.2.1. North America
  • 11.2.2. Europe
  • 11.2.3. Asia Pacific
  • 11.2.4. Latin America
  • 11.2.5. Middle East & Africa
• 11.3. Market Attractiveness Analysis, by Region

12. North America Nucleic Acid Therapeutics Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Therapy Type, 2020 - 2035
  • 12.2.1. Antisense oligonucleotides (ASOs)
  • 12.2.2. Small interfering R(siRNA)
  • 12.2.3. Gene Therapies
  • 12.2.4. Aptamers
  • 12.2.5. Others
• 12.3. Market Value Forecast, by Delivery Method, 2020 - 2035
  • 12.3.1. Viral vector-based Delivery Systems
  • 12.3.2. Non-viral Delivery Systems
• 12.4. Market Value Forecast, by Route of Administration, 2020 - 2035
  • 12.4.1. Intravenous
  • 12.4.2. Subcutaneous
  • 12.4.3. Others
• 12.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
  • 12.5.1. Neuromuscular Disorder
  • 12.5.2. Metabolic Disorders
  • 12.5.3. Cardiovascular Disorders
  • 12.5.4. Ophthalmological Disorders
  • 12.5.5. Oncological Disorders
  • 12.5.6. Others
• 12.6. Market Value Forecast, by End-user, 2020 - 2035
  • 12.6.1. Hospitals
  • 12.6.2. Academic and Research Institutes
  • 12.6.3. Others
• 12.7. Market Value Forecast, by Country, 2020 - 2035
  • 12.7.1. U.S.
  • 12.7.2. Canada
• 12.8. Market Attractiveness Analysis
  • 12.8.1. By Therapy Type
  • 12.8.2. By Delivery Method
  • 12.8.3. By Route of Administration
  • 12.8.4. By Therapeutic Area
  • 12.8.5. By End-user
  • 12.8.6. By Country

13. Europe Nucleic Acid Therapeutics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Therapy Type, 2020 - 2035
  • 13.2.1. Antisense oligonucleotides (ASOs)
  • 13.2.2. Small interfering R(siRNA)
  • 13.2.3. Gene Therapies
  • 13.2.4. Aptamers
  • 13.2.5. Others
• 13.3. Market Value Forecast, by Delivery Method, 2020 - 2035
  • 13.3.1. Viral vector-based Delivery Systems
  • 13.3.2. Non-viral Delivery Systems
• 13.4. Market Value Forecast, by Route of Administration, 2020 - 2035
  • 13.4.1. Intravenous
  • 13.4.2. Subcutaneous
  • 13.4.3. Others
• 13.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
  • 13.5.1. Neuromuscular Disorder
  • 13.5.2. Metabolic Disorders
  • 13.5.3. Cardiovascular Disorders
  • 13.5.4. Ophthalmological Disorders
  • 13.5.5. Oncological Disorders
  • 13.5.6. Others
• 13.6. Market Value Forecast, by End-user, 2020 - 2035
  • 13.6.1. Hospitals
  • 13.6.2. Academic and Research Institutes
  • 13.6.3. Others
• 13.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
  • 13.7.1. Germany
  • 13.7.2. UK
  • 13.7.3. France
  • 13.7.4. Italy
  • 13.7.5. Spain
  • 13.7.6. Rest of Europe
• 13.8. Market Attractiveness Analysis
  • 13.8.1. By Therapy Type
  • 13.8.2. By Delivery Method
  • 13.8.3. By Route of Administration
  • 13.8.4. By Therapeutic Area
  • 13.8.5. By End-user
  • 13.8.6. By Country/Sub-region

14. Asia Pacific Nucleic Acid Therapeutics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Therapy Type, 2020 - 2035
  • 14.2.1. Antisense oligonucleotides (ASOs)
  • 14.2.2. Small interfering R(siRNA)
  • 14.2.3. Gene Therapies
  • 14.2.4. Aptamers
  • 14.2.5. Others
• 14.3. Market Value Forecast, by Delivery Method, 2020 - 2035
  • 14.3.1. Viral vector-based Delivery Systems
  • 14.3.2. Non-viral Delivery Systems
• 14.4. Market Value Forecast, by Route of Administration, 2020 - 2035
  • 14.4.1. Intravenous
  • 14.4.2. Subcutaneous
  • 14.4.3. Others
• 14.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
  • 14.5.1. Neuromuscular Disorder
  • 14.5.2. Metabolic Disorders
  • 14.5.3. Cardiovascular Disorders
  • 14.5.4. Ophthalmological Disorders
  • 14.5.5. Oncological Disorders
  • 14.5.6. Others
• 14.6. Market Value Forecast, by End-user, 2020 - 2035
  • 14.6.1. Hospitals
  • 14.6.2. Academic and Research Institutes
  • 14.6.3. Others
• 14.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
  • 14.7.1. China
  • 14.7.2. Japan
  • 14.7.3. India
  • 14.7.4. Australia & New Zealand
  • 14.7.5. Rest of Asia Pacific
• 14.8. Market Attractiveness Analysis
  • 14.8.1. By Therapy Type
  • 14.8.2. By Delivery Method
  • 14.8.3. By Route of Administration
  • 14.8.4. By Therapeutic Area
  • 14.8.5. By End-user
  • 14.8.6. By Country/Sub-region

15. Latin America Nucleic Acid Therapeutics Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Therapy Type, 2020 - 2035
  • 15.2.1. Antisense oligonucleotides (ASOs)
  • 15.2.2. Small interfering R(siRNA)
  • 15.2.3. Gene Therapies
  • 15.2.4. Aptamers
  • 15.2.5. Others
• 15.3. Market Value Forecast, by Delivery Method, 2020 - 2035
  • 15.3.1. Viral vector-based Delivery Systems
  • 15.3.2. Non-viral Delivery Systems
• 15.4. Market Value Forecast, by Route of Administration, 2020 - 2035
  • 15.4.1. Intravenous
  • 15.4.2. Subcutaneous
  • 15.4.3. Others
• 15.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
  • 15.5.1. Neuromuscular Disorder
  • 15.5.2. Metabolic Disorders
  • 15.5.3. Cardiovascular Disorders
  • 15.5.4. Ophthalmological Disorders
  • 15.5.5. Oncological Disorders
  • 15.5.6. Others
• 15.6. Market Value Forecast, by End-user, 2020 - 2035
  • 15.6.1. Hospitals
  • 15.6.2. Academic and Research Institutes
  • 15.6.3. Others
• 15.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
  • 15.7.1. Brazil
  • 15.7.2. Mexico
  • 15.7.3. Rest of Latin America
• 15.8. Market Attractiveness Analysis
  • 15.8.1. By Therapy Type
  • 15.8.2. By Delivery Method
  • 15.8.3. By Route of Administration
  • 15.8.4. By Therapeutic Area
  • 15.8.5. By End-user
  • 15.8.6. By Country/Sub-region

16. Middle East & Africa Nucleic Acid Therapeutics Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast, by Therapy Type, 2020 - 2035
  • 16.2.1. Antisense oligonucleotides (ASOs)
  • 16.2.2. Small interfering R(siRNA)
  • 16.2.3. Gene Therapies
  • 16.2.4. Aptamers
  • 16.2.5. Others
• 16.3. Market Value Forecast, by Delivery Method, 2020 - 2035
  • 16.3.1. Viral vector-based Delivery Systems
  • 16.3.2. Non-viral Delivery Systems
• 16.4. Market Value Forecast, by Route of Administration, 2020 - 2035
  • 16.4.1. Intravenous
  • 16.4.2. Subcutaneous
  • 16.4.3. Others
• 16.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
  • 16.5.1. Neuromuscular Disorder
  • 16.5.2. Metabolic Disorders
  • 16.5.3. Cardiovascular Disorders
  • 16.5.4. Ophthalmological Disorders
  • 16.5.5. Oncological Disorders
  • 16.5.6. Others
• 16.6. Market Value Forecast, by End-user, 2020 - 2035
  • 16.6.1. Hospitals
  • 16.6.2. Academic and Research Institutes
  • 16.6.3. Others
• 16.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
  • 16.7.1. GCC Countries
  • 16.7.2. South Africa
  • 16.7.3. Rest of Middle East & Africa
• 16.8. Market Attractiveness Analysis
  • 16.8.1. By Therapy Type
  • 16.8.2. By Delivery Method
  • 16.8.3. By Route of Administration
  • 16.8.4. By Therapeutic Area
  • 16.8.5. By End-user
  • 16.8.6. By Country/Sub-region

17. Competition Landscape

• 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 17.2. Market Share Analysis, by Company (2024)
• 17.3. Company Profiles
  • 17.3.1. Novartis AG
    • 17.3.1.1. Company Overview
    • 17.3.1.2. Financial Overview
    • 17.3.1.3. Product Portfolio
    • 17.3.1.4. Business Strategies
    • 17.3.1.5. Recent Developments
  • 17.3.2. Pfizer, Inc.
    • 17.3.2.1. Company Overview
    • 17.3.2.2. Financial Overview
    • 17.3.2.3. Product Portfolio
    • 17.3.2.4. Business Strategies
    • 17.3.2.5. Recent Developments
  • 17.3.3. Sanofi
    • 17.3.3.1. Company Overview
    • 17.3.3.2. Financial Overview
    • 17.3.3.3. Product Portfolio
    • 17.3.3.4. Business Strategies
    • 17.3.3.5. Recent Developments
  • 17.3.4. Novo Nordisk A/S
    • 17.3.4.1. Company Overview
    • 17.3.4.2. Financial Overview
    • 17.3.4.3. Product Portfolio
    • 17.3.4.4. Business Strategies
    • 17.3.4.5. Recent Developments
  • 17.3.5. AstraZeneca plc
    • 17.3.5.1. Company Overview
    • 17.3.5.2. Financial Overview
    • 17.3.5.3. Product Portfolio
    • 17.3.5.4. Business Strategies
    • 17.3.5.5. Recent Developments
  • 17.3.6. Alnylam Pharmaceuticals, Inc.
    • 17.3.6.1. Company Overview
    • 17.3.6.2. Financial Overview
    • 17.3.6.3. Product Portfolio
    • 17.3.6.4. Business Strategies
    • 17.3.6.5. Recent Developments
  • 17.3.7. Amgen Inc
    • 17.3.7.1. Company Overview
    • 17.3.7.2. Financial Overview
    • 17.3.7.3. Product Portfolio
    • 17.3.7.4. Business Strategies
    • 17.3.7.5. Recent Developments
  • 17.3.8. Sarepta Therapeutics, Inc.
    • 17.3.8.1. Company Overview
    • 17.3.8.2. Financial Overview
    • 17.3.8.3. Product Portfolio
    • 17.3.8.4. Business Strategies
    • 17.3.8.5. Recent Developments
  • 17.3.9. Bluebird Bio, Inc
    • 17.3.9.1. Company Overview
    • 17.3.9.2. Financial Overview
    • 17.3.9.3. Product Portfolio
    • 17.3.9.4. Business Strategies
    • 17.3.9.5. Recent Developments
  • 17.3.10. CSL Behring LLC
    • 17.3.10.1. Company Overview
    • 17.3.10.2. Financial Overview
    • 17.3.10.3. Product Portfolio
    • 17.3.10.4. Business Strategies
    • 17.3.10.5. Recent Developments
  • 17.3.11. Ferring Pharmaceuticals Inc.
    • 17.3.11.1. Company Overview
    • 17.3.11.2. Financial Overview
    • 17.3.11.3. Product Portfolio
    • 17.3.11.4. Business Strategies
    • 17.3.11.5. Recent Developments
  • 17.3.12. Krystal Biotech, Inc.
    • 17.3.12.1. Company Overview
    • 17.3.12.2. Financial Overview
    • 17.3.12.3. Product Portfolio
    • 17.3.12.4. Business Strategies
    • 17.3.12.5. Recent Developments
  • 17.3.13. PTC Therapeutics, Inc.
    • 17.3.13.1. Company Overview
    • 17.3.13.2. Financial Overview
    • 17.3.13.3. Product Portfolio
    • 17.3.13.4. Business Strategies
    • 17.3.13.5. Recent Developments
  • 17.3.14. Jazz Pharmaceuticals plc
    • 17.3.14.1. Company Overview
    • 17.3.14.2. Financial Overview
    • 17.3.14.3. Product Portfolio
    • 17.3.14.4. Business Strategies
    • 17.3.14.5. Recent Developments
  • 17.3.15. Astellas Pharma Inc.
    • 17.3.15.1. Company Overview
    • 17.3.15.2. Financial Overview
    • 17.3.15.3. Product Portfolio
    • 17.3.15.4. Business Strategies
    • 17.3.15.5. Recent Developments